Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Trial ID or NCT#

NCT01707264

Status

not recruiting iconNOT RECRUITING

Purpose

Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.

Official Title

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Males and females aged ≥18 years; 2. ECOG performance status (PS) 0-2; 3. Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not eligible); 4. Received at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis; 5. Have adequate organ function; 6. Ability to understand and willingness to sign informed consent prior to initiation of any study procedures.
Exclusion Criteria:
  1. 1. Secondary or familial amyloidosis; 2. Life expectancy of < 3 months; 3. Symptomatic multiple myeloma; 4. Hypersensitivities to other monoclonal antibodies; 5. Known HIV infection; 6. Women who are lactating; 7. Any other condition or prior therapy, which in the opinion of the PI, would make the subject unsuitable for the study.
View All Criteria
Show Less

Investigator(s)

Rondeep Brar
Rondeep Brar
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Hematology
Michaela Liedtke
Michaela Liedtke
Hematologist-Oncologist
Associate Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov